Peroxisome Proliferator-Activated Receptor Agonists in Alzheimer's Disease Management

Peroxisome proliferator-activated receptor (PPAR) agonists have emerged as multifaceted agents in Alzheimer’s disease (AD), exerting anti-inflammatory, antioxidant and metabolic regulatory effects in the central nervous system. By activating nuclear receptors of the PPAR family—chiefly the γ isoform—these compounds modulate gene expression programmes that attenuate neuroinflammation, enhance clearance of amyloid-β (Aβ) species and support mitochondrial function. Preclinical models have shown that PPAR agonists reduce microglial and astrocyte activation, suppress pro-inflammatory cytokine release, down-regulate β-secretase activity and improve synaptic plasticity. Moreover, these agents may bolster vascular clearance of Aβ via upregulation of transport proteins and promote neuronal resilience through co-activation of Nrf2-mediated antioxidant pathways. Translation to human studies remains under way, with attention to dose optimisation and patient stratification.

Research from Nature Portfolio

Low-dose administration of a PPARγ agonist in a senescence-accelerated mouse strain improved spatial memory and decreased hippocampal Aβ deposition by upregulating low-density lipoprotein receptor-related protein 1 (LRP1), which mediates Aβ efflux across the blood–brain barrier. Notably, a lower dose achieved cognitive benefit without adverse metabolic effects typical of diabetes therapy, highlighting the potential for repurposing this class of drugs at sub-clinical doses in early AD.

Peroxisome Proliferator-Activated Receptor Agonists in Alzheimer's Disease Management publication trend

The graph below shows the total number of articles in peroxisome proliferator-activated receptor agonists in alzheimer's disease management across all publications each year (not limited to Nature Index journals).

Technical terms

Peroxisome proliferator-activated receptor γ (PPARγ): A nuclear receptor that regulates genes involved in inflammation, lipid metabolism and antioxidant defence.

PPAR agonist: A small molecule that binds to and activates a PPAR isoform, leading to transcriptional changes.

Amyloid-β oligomer (AβO): Soluble aggregates of amyloid-β peptide implicated in synaptic dysfunction and neurotoxicity in AD.

Neuroinflammation: The activation of glial cells and release of inflammatory mediators within the central nervous system.

Microglia: Resident immune cells of the brain that mediate phagocytosis and inflammatory responses.

Low-density lipoprotein receptor-related protein 1 (LRP1): A transporter protein involved in the efflux of Aβ peptides from the brain across the blood–brain barrier.

References

1. Aβ Oligomer Toxicity-Reducing Therapy for the Prevention of Alzheimer’s Disease: Importance of the Nrf2 and PPARγ Pathways. Cells (2023).
2. Polygalacic acid attenuates cognitive impairment by regulating inflammation through PPARγ/NF‐κB signaling pathway. CNS Neuroscience & Therapeutics (2024).
3. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice. Brain (2005).
4. Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus. Scientific Reports (2019).